RICHMOND, Va., Nov. 17, 2015 (GLOBE NEWSWIRE) — A 10-month pilot of the ALRT remote monitoring system for diabetes by the Kansas City Metropolitan Physician Association (KCMPA) has found significant improvement in glycemic control for those patients who used the system compared to those who dropped out of the pilot.
Patients participating in the pilot program of the ALRT system experienced an average A1C reduction of 1.22% while patients who dropped from the program prior to the three-month threshold saw A1C levels rise by+0.66%. The Centers for Disease Control (CDC) reports that every 1% reduction in A1C lowers the risk of some costly long-term diabetes complications by 40%.
“The goal of the program was to demonstrate the ability of the ALRT system to improve treatment adherence and health outcomes for patients, and enable physicians to intensively manage a population of diabetes patients remotely,” said Dr. Nathan Granger, President of KCMPA. “The results of the pilot exceeded the high expectations we had at the start of the program.”
“We used the ALRT system on some of our most difficult insulin-requiring patients . . . patients who have eluded improvement for many years,” Dr. Granger said. “We found it to be an excellent tool to finally get these patients to their target A1C levels.”
The ALRT system, developed by ALR Technologies Inc. (OTCQG: ALRT), was tested in KCMPA-affiliated clinics across the Greater Kansas City region as a diabetes management component of KCMPA’s Quality Improvement Plan designed to lower A1C scores for some of their most challenging patients. The pilot was so successful that one participating clinic decided to pay for the ALRT program for its patients before the final results were tabulated.
“We partnered with the Mid-America Coalition on Healthcare, the sponsor of the pilot, and KCMPA to show that the ALRT system can increase efficiency for care teams and improve health outcomes for patients,” said Bill Smith, President of ALR Technologies. “The success of this pilot means we can also deliver a range of associated benefits such as improved performance scores for medical practices and savings for employers and payers who need an effective way to manage the skyrocketing cost of diabetes.”
The detailed results of the pilot program can be found here: http://www.alrt.com/Media/Default/Downloads/MACHC%20White%20Paper%20(final).pdf
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.
Contact: Philip Murphy: 203.947.2827 email: firstname.lastname@example.org
This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate”, “expect”, “anticipate”, “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the Company’s quarterly filings with the Securities Exchange Commission.
Philip Murphy: 203.947.2827 email: